Search

Ocular Therapeutix Inc

Închisă

SectorSănătate

9.99 -1.19

Rezumat

Modificarea prețului

24h

Curent

Minim

9.88

Maxim

10.08

Indicatori cheie

By Trading Economics

Venit

9.8M

-79M

Vânzări

2.7M

13M

EPS

-0.35

Marjă de profit

-584.512

Angajați

325

EBITDA

10M

-74M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+152.75% upside

Dividende

By Acuity

Următoarele câștiguri

3 nov. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

462M

2.4B

Deschiderea anterioară

11.18

Închiderea anterioară

9.99

Sentimentul știrilor

By Acuity

100%

0%

320 / 339 Clasament în Healthcare

Ocular Therapeutix Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 sept. 2026, 23:25 UTC

Ocular Therapeutix Inc is trading higher in after-market hours, rising from a low post-close and currently above Friday's close but below its 20-day moving average.

17 sept. 2026, 20:07 UTC

Ocular Therapeutix Inc is advancing, maintaining gains from Wednesday, despite earlier pulling back from a session high while remaining below its 20-day moving average.

16 sept. 2026, 20:10 UTC

Event
Social Media

Ocular Therapeutix Inc shares fell sharply despite positive social media sentiment about its NDA filing for Axpaxli and recent FDA discussions.

15 sept. 2026, 22:02 UTC

Event

Ocular Therapeutix Inc. plans to submit its New Drug Application by Q4 2026, but shares are lower in after-market hours amid broader economic concerns.

14 sept. 2026, 19:17 UTC

Ocular Therapeutix Inc is trading higher during Monday's session, having gained since Friday's close, despite a negative broader market sentiment.

11 sept. 2026, 23:51 UTC

Ocular Therapeutix Inc shares are higher in after-market hours, supported by improved fiscal management reflected in a narrower-than-expected budget deficit of $167 billion for August.

10 sept. 2026, 22:26 UTC

Ocular Therapeutix Inc shares are lower in after-market hours, with no specific news identified to explain the decline. The stock retraced from an initial rise.

9 sept. 2026, 23:36 UTC

Ocular Therapeutix shares are lower in after-market trading, continuing a decline since Wednesday's close, despite remaining near the upper end of their one-month range.

8 sept. 2026, 20:02 UTC

Ocular Therapeutix Inc shares are higher during Tuesday's market hours, despite earlier pulling back from a session high. No specific news was identified.

3 sept. 2026, 20:01 UTC

Ocular Therapeutix Inc's shares are lower today, breaking a trend of higher closes since Wednesday. No specific news was identified to explain the decline.

2 sept. 2026, 23:31 UTC

Ocular Therapeutix shares were roughly flat in after-market hours. The broader market reacted to a weaker-than-expected ADP payrolls report.

1 sept. 2026, 19:46 UTC

Ocular Therapeutix Inc's shares are higher today, rebounding from earlier volatility and remaining well above the 20-day moving average.

31 aug. 2026, 21:01 UTC

Ocular Therapeutix Inc is trading higher in after-market hours, showing strength despite broader market pressure from hawkish Fed remarks. No specific news was identified.

28 aug. 2026, 20:08 UTC

Ocular Therapeutix Inc shares are lower today, reflecting broader market declines amid rising U.S. Treasury yields and inflation concerns. No specific company news was identified.

27 aug. 2026, 21:01 UTC

Ocular Therapeutix Inc shares are trading lower in after-market hours. No specific company news was identified to explain this movement.

26 aug. 2026, 19:36 UTC

Ocular Therapeutix Inc shares are lower today, with no specific news identified. This follows U.S. PCE data indicating inflationary pressures.

24 aug. 2026, 20:06 UTC

Social Media

Ocular Therapeutix Inc. shares are lower amid a lawsuit from EyePoint, Inc. and broader market pressures, despite a brief rebound earlier in the session.

22 aug. 2026, 00:02 UTC

Ocular Therapeutix Inc is trading higher in after-market hours, maintaining momentum from Friday's close amid a broadly positive market performance.

21 aug. 2026, 21:01 UTC

Ocular Therapeutix Inc shares are higher in after-market trading, reflecting strong performance amid positive sentiment in related sectors and developments in the cryptocurrency market.

20 aug. 2026, 20:02 UTC

Ocular Therapeutix Inc is lower today amid broader market declines following Walmart's disappointing sales growth and guidance, contributing to increased selling pressure.

19 aug. 2026, 23:21 UTC

Ocular Therapeutix Inc shows modest gains in after-market trading, with no specific news identified for the price movement. The stock remains above its 20-day moving average.

18 aug. 2026, 22:26 UTC

Social Media

Ocular Therapeutix shares rise in after-market hours after Cowen set a $20 price target, and Baird raised its target to $30 amid competitive advantages.

17 aug. 2026, 23:11 UTC

Ocular Therapeutix Inc's shares are higher in after-market trading, continuing a strong performance since Monday's close and reaching a notable high.

14 aug. 2026, 19:46 UTC

Ocular Therapeutix Inc shares are lower amid a decline in the Pharmaceuticals sub-sector. The stock has traded down since Thursday's close.

13 aug. 2026, 23:16 UTC

Ocular Therapeutix Inc's shares are lower in after-market hours, reflecting a slight decline since Thursday's close. No specific news was identified for this movement.

12 aug. 2026, 20:01 UTC

Ocular Therapeutix Inc shares are higher in Wednesday's session, with elevated trading volume. The stock remains above its 20-day moving average.

11 aug. 2026, 23:21 UTC

Ocular Therapeutix Inc shares fell during after-market hours, reaching a session low before slightly recovering. Broader market dynamics may be influencing this decline.

10 aug. 2026, 20:06 UTC

Ocular Therapeutix Inc is trading higher, recovering above its 20-day moving average amid a broader trend of three consecutive sessions finishing higher.

7 aug. 2026, 21:01 UTC

Ocular Therapeutix Inc shares are higher in after-market hours, continuing an upward trend after three consecutive sessions of gains.

6 aug. 2026, 20:06 UTC

Ocular Therapeutix Inc shares are higher during Thursday's session, recovering from an earlier dip despite trading below their 20-day moving average.

Comparație

Modificare preț

Ocular Therapeutix Inc Așteptări

Obiectiv de preț

By TipRanks

152.75% sus

Prognoză pe 12 luni

Medie 25.25 USD  152.75%

Maxim 31 USD

Minim 18 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOcular Therapeutix Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

9

Cumpărare

0

Păstrare

0

Vânzare

Sentiment

By Acuity

320 / 339 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.